---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-21-056375"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2021-11-12T23:59:59+00:00"
generated_at: "2026-06-28T09:08:03.088050+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kintara names Robert Hoffman as CEO; Saiid Zarrabian transitions to Head of Strategic Partnerships

## Summary
- Robert E. Hoffman appointed President and CEO effective Nov 8, 2021; previously Chairman.
- Saiid Zarrabian steps down as CEO, becomes Head of Strategic Partnerships.
- Hoffman receives $551k base salary, 3,519,170 stock option grant (4-yr vest), target bonus up to 50%.
- Zarrabian's new salary $285k, target bonus up to 40%; unvested options now tied to milestones.

## SEC filing metadata
- accession: 0001564590-21-056375
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2021-11-12T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/0001564590-21-056375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/ktra-8k_20211108.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-21-056375
- JSON: https://secwatch.observer/filing/0001564590-21-056375.json
- Plain text: https://secwatch.observer/filing/0001564590-21-056375.txt

## Key facts
- Executive change
  Robert E. Hoffman was appointed as President and Chief Executive Officer at TuHURA Biosciences, Inc./NV.
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: On November 8, 2021, the Board of Directors (the “Board”) of Kintara Therapeutics, Inc. (the “Company”) appointed Robert E. Hoffman, the then current Chairman of the Board, to succeed Saiid Zarrabian as President and Chief Executive Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/0001564590-21-056375-index.htm
- Executive change
  Saiid Zarrabian changed role as Head of Strategic Partnerships at TuHURA Biosciences, Inc./NV.
  - Action: transitioned
  - Role: Head of Strategic Partnerships
  source text: on November 8, 2021, the Board and Mr. Zarrabian mutually agreed that Mr. Zarrabian would immediately transition into the role of Head of Strategic Partnerships.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1498382/000156459021056375/0001564590-21-056375-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.